• Home
  •  / Teva Pharmaceuticals

Teva Pharmaceuticals

OverviewSuggest Edit

Teva Pharmaceuticals is a global pharmaceutical company. Its product and service portfolio includes generic medicines, biopharmaceuticals, specialty medicines, OTC products, a distribution business, API and contract manufacturing. The company develops, manufacture,s and sell generic medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Teva offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, high-potency drugs, and cytotoxic substances, in both parenteral and solid dosage forms.

TypePublic
Founded1901
HQPetah Tikva, ILMap
Websitetevapharm.com
Employee Ratings3.7More
Overall CultureDMore
View Jobs (583)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)40,039(-5%)
Job Openings583
Revenue (FY, 2020)$16.7 B(-1%)
Share Price (Jun 2021)₪35(+2%)
Cybersecurity ratingBMore

Key People/Management at Teva Pharmaceuticals

Kare Schultz

Kare Schultz

Director and President and Chief Executive Officer
Richard Daniell

Richard Daniell

Executive Vice President, European Commercial
Sven Dethlefs

Sven Dethlefs

Executive Vice President, Global Marketing & Portfolio
Eric Drapé

Eric Drapé

Executive Vice President, Global Operations
Hafrun Fridriksdottir

Hafrun Fridriksdottir

Executive Vice President, Global R&D
Gianfranco Nazzi

Gianfranco Nazzi

Executive Vice President, International Markets Commercial
Show more

Teva Pharmaceuticals Office Locations

Teva Pharmaceuticals has offices in Petah Tikva, Be’er Sheva, Parsippany-Troy Hills, Villa Adelina and in 72 other locations
Petah Tikva, IL (HQ)
5 Basel St
Be’er Sheva, IL
Neot Hovav Eco-Industrial Park, Emek Sara
Villa Adelina, AR
Juan José Castelli 6701
Macquarie Park, AU
37 Epping Rd
Minsk, BY
praspekt Niezaliežnasci 169
Antwerpen, BE
Laarstraat 16
Show all (78)

Teva Pharmaceuticals Financials and Metrics

Teva Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Teva Pharmaceuticals's revenue was reported to be $16.66 b in FY, 2020
USD

Revenue (FY, 2020)

16.7b

Gross profit (FY, 2020)

7.7b

Gross profit margin (FY, 2020), %

46.4%

Net income (FY, 2020)

(4.1b)

EBIT (FY, 2020)

(3.6b)

Market capitalization (3-Jun-2021)

38.6b

Closing stock price (3-Jun-2021)

35.0

Cash (31-Dec-2020)

2.2b

EV

63.3b
Teva Pharmaceuticals's current market capitalization is ₪38.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

22.4b18.9b16.9b16.7b

Revenue growth, %

2%(16%)(10%)

Cost of goods sold

11.6b10.6b9.4b8.9b

Gross profit

10.8b8.3b7.5b7.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.1b4.7b4.5b4.3b4.3b4.3b4.4b3.9b4.0b

Cost of goods sold

2.7b2.6b2.5b2.4b2.4b2.4b2.3b2.1b2.1b

Gross profit

2.3b2.1b2.0b1.9b1.9b1.8b2.1b1.8b1.9b

Gross profit Margin, %

46%44%45%43%44%43%47%46%47%
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

963.0m1.8b2.0b2.2b

Accounts Receivable

7.1b5.8b5.7b4.6b

Prepaid Expenses

1.1b899.0m870.0m945.0m

Inventories

4.9b4.7b4.4b4.4b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

1.4b1.9b1.9b2.0b2.2b1.2b1.8b2.4b1.8b

Accounts Receivable

6.3b6.1b5.7b5.1b5.3b5.3b5.2b4.5b4.4b

Prepaid Expenses

1.1b1.1b911.0m969.0m1.1b976.0m977.0m956.0m895.0m

Inventories

5.1b5.0b4.9b4.8b4.9b4.6b4.3b4.4b4.5b
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.4b)(2.5b)(1.0b)(4.1b)

Depreciation and Amortization

2.1b1.8b1.7b1.6b

Inventories

199.0m26.0m271.0m(41.0m)

Accounts Payable

(1.8b)(500.0m)643.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

1.1b968.0m771.0m(97.0m)(768.0m)(1.1b)25.0m78.0m(4.3b)

Depreciation and Amortization

507.0m986.0m1.5b443.0m893.0m1.3b399.0m781.0m1.2b

Cash From Operating Activities

1.5b1.7b2.1b112.0m(115.0m)210.0m305.0m578.0m885.0m

Purchases of PP&E

(163.0m)(299.0m)(438.0m)(125.0m)(237.0m)(406.0m)(128.0m)(259.0m)(402.0m)
show all
USDFY, 2017

Revenue/Employee

432.2k

Debt/Equity

1.7 x

Debt/Assets

0.5 x

Financial Leverage

3.8 x

P/E Ratio

(1.2)
Show all financial metrics

Teva Pharmaceuticals Operating Metrics

FY, 2017FY, 2018FY, 2019

Facilities

889090

Facilities (United States)

17

Facilities (Europe)

333134

Facilities (Rest of World)

38
Show all operating metrics

Teva Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
AndaNetOctober 03, 2016$500 m
ActavisAugust 02, 2016$40.5 b
RimsaMarch 04, 2016$2.3 b
Gecko Health InnovationsSeptember 25, 2015
Auspex PharmaceuticalsApril 04, 2015$3.5 b
Labrys BiologicsJune 03, 2014$825 m
NuPatheJanuary 21, 2014$144 m
MicroDose TherapeutxJune 17, 2013$165 m
CephalonOctober 14, 2011$6.8 b
Barr PharmaceuticalsJuly 18, 2008
Show more

Teva Pharmaceuticals Revenue Breakdown

Embed Graph

Teva Pharmaceuticals revenue breakdown by geographic segment: 54.8% from North America, 30.8% from Europe and 14.4% from International Markets

Human Capital Metrics

Source: www.tevapharm.com
Embed Graph
Show all human capital metrics

Teva Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about our premium products
SecurityScorecard logo

Teva Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Teva Pharmaceuticals Online and Social Media Presence

Teva Pharmaceuticals's Trends

Embed Graph

Teva Pharmaceuticals Company Culture

  • Overall Culture

    D

    59/100

  • CEO Rating

    C-

    63/100

  • Compensation

    B+

    74/100

  • Diversity

    D+

    59/100

Learn more on Comparably

Teva Pharmaceuticals News and Updates

February 05, 2021

Global Anti-Parkinson Drugs Market Report 2020-2030: Major Players are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc. and Mylan

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Anti-Parkinson Drugs Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Anti-Parkinson Drugs Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists,...
December 11, 2020

Teva launches employee 'Villyge' to improve work-life balance

Teva Pharmaceuticals has partnered with Villyge to help its parent employees with a post-COVID-19 work/life balance
December 07, 2020

‘It has made a real difference’: Increasing access to medicines in Haiti

Doctors at St. Luke’s Hospital in Haiti were in urgent need of medicines to treat patients across several units including trauma, cancer and outpatient centers. Through Teva’s ongoing partnership with on-the-ground logistics experts Direct Relief, our medicines have been able to reach those in most …
November 28, 2020

EU Fines Teva $72 Million For Illegally Delaying Cheaper Generic Drug

The European Commission said on Thursday that it fined Teva pharmaceuticals, the largest generic drug manufacturer in the world, €60.5 million (US$72 million) for illegally delaying the entry of a cheaper generic version of a drug for sleep disorders
November 20, 2020

Teva dispenses $2.6 million to resolve ERISA claims

Teva Pharmaceuticals USA Inc. agreed to pay $2.6 million to settle claims by current and former participants in the company's 401(k) that plan fiduciaries violated ERISA by failing to reduce fees and to offer less expensive investment options that are similar to existing ones
November 05, 2020

Teva Reports Third Quarter 2020 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2020
Show more

 Teva Pharmaceuticals Frequently Asked Questions

  • When was Teva Pharmaceuticals founded?

    Teva Pharmaceuticals was founded in 1901.

  • Who are Teva Pharmaceuticals key executives?

    Teva Pharmaceuticals's key executives are Kare Schultz, Richard Daniell and Sven Dethlefs.

  • How many employees does Teva Pharmaceuticals have?

    Teva Pharmaceuticals has 40,039 employees.

  • What is Teva Pharmaceuticals revenue?

    Latest Teva Pharmaceuticals annual revenue is $16.7 b.

  • What is Teva Pharmaceuticals revenue per employee?

    Latest Teva Pharmaceuticals revenue per employee is $416.1 k.

  • Who are Teva Pharmaceuticals competitors?

    Competitors of Teva Pharmaceuticals include Viatris, WuXi AppTec and Merck.

  • Where is Teva Pharmaceuticals headquarters?

    Teva Pharmaceuticals headquarters is located at 5 Basel St, Petah Tikva.

  • Where are Teva Pharmaceuticals offices?

    Teva Pharmaceuticals has offices in Petah Tikva, Be’er Sheva, Parsippany-Troy Hills, Villa Adelina and in 72 other locations.

  • How many offices does Teva Pharmaceuticals have?

    Teva Pharmaceuticals has 78 offices.